[1] |
SONG Qiuying, TAO Chenjuan, WU Zhihao, XIE Zhefeng, LIU Haijun, CHEN Binbin.
Effect of antithrombotic therapy selection on stroke recurrence based on drug gene polymorphism and thromboelastography
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(9): 1035-1041.
|
[2] |
YANG Xuerong, FANG Jing, CHEN Lu, YANG Yong.
Advances in population pharmacokinetics of voriconazole in special populations
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(12): 1367-1379.
|
[3] |
WAN Shujun, ZHANG Mengying, CHEN Qilei, ZHONG Min, ZHU Xiaolong, ZHANG Yingying, LV Kun.
Clinical value of genetic polymorphism analysis of hypertension drugs for individualized treatment of hypertension patients in the southern Anhui region
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(1): 68-75.
|
[4] |
HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang.
Comparison of calculation results of five population pharmacokinetic analysis tools
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
|
[5] |
LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua.
Research progress in population pharmacokinetics of rituximab
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
|
[6] |
LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang.
Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
|
[7] |
PAN Shu, WU Yijin, ZHANG Sasa, WANG Qihai, LUO Tingting, YIN Qin.
Pharmacokinetics of methotrexate mediated by organic anion transporter 3 in adjuvant induced arthritis rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 516-525.
|
[8] |
LIU Wei, XUE Junsheng, YU Zhiheng, WANG Ziyu, CHEN Rong, ZHOU Tianyan.
Interpretation of pharmacokinetic-based criteria for supporting alternative dosing regimens of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer guidance for industry
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 86-94.
|
[9] |
LIN Liangmo, FU Xiangjun, ZHONG Lili, WANG Hefang, WU Qiongshi, XIAO Jian.
Establishment of population pharmacokinetics model of vancomycin in patients with Neutropenia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1014-1022.
|
[10] |
XU Guofang, ZHANG Sisen, LIU Ping, MEI Jiazhuan, LIU Weiwei, LIU Ya'ou, QI Qi.
Population pharmacokinetics of capecitabine in Chinese breast cancer patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 552-559.
|
[11] |
LI Wenchao, BAI Xiangrong, LI Xiaoling, JIANG Dechun.
Population pharmacokinetics/pharmacodynamics of tigecycline in the treatment of different infectious diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1265-1272.
|
[12] |
GUO Xianzhong, LIN Rongfang, LIN Weiwei.
Development of software for individualizing dosage regimens of vancomycin based on population pharmacokinetics models
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 30-39.
|
[13] |
LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang.
Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.
|
[14] |
LI Jian, YANG Jinbo, WANG Yuzhu.
Discussion on the format and content of new drug population pharmacokinetic study report
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 546-549.
|
[15] |
XU Gaoqi, ZHANG Yiwen, ZHENG Xiaowei, LIU Yujia, LI Li, HUANG Ping.
Missed and remedial dosage regimens of erlotinib by Monte Carlo simulation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 540-545.
|